Pibrentasvir
Mavyret, Maviret (pibrentasvir) is a small molecule pharmaceutical. Pibrentasvir was first approved as Mavyret on 2017-07-26. It is used to treat hepatitis c in the USA. It has been approved in Europe to treat chronic hepatitis c. Mavyret's patents are valid until 2035-06-05 (FDA).
| Trade Name | Maviret |
|---|---|
| Common Name | Pibrentasvir |
| Indication | chronic hepatitis c, hepatitis c |
| Drug Class | Antivirals: NS5A inhibitors |
